Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

DipHIV > HIV post exposure prophylaxis (PEP) > Flashcards

HIV post exposure prophylaxis (PEP) Flashcards

1
Q

What are the 3 broad categories through which HIV exposure may occur?

A

1) Occupational exposure
2) Community non-occupational exposure
3) Sexual exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How long does it take for HIV to start to replicate once it has crossed the mucosal barrier?

A

Up to FORTY EIGHT (48) hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

When is HIV first detected in the blood?

A

FIVE (5) days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Within what time frame has PEP been shown to reduce dissemination and replication of HIV virus?

A 
start within 
SEVENTY TWO (72) hours
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

UK surveillance data of occupational exposure to HIV - summarise

A

Since 2004 all occupational exposures started on PEP have no new cases HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Brazil study that support PEPSE use - summarise

A

MSM in Brazil
Overall HIV incidence similar to expected
PEP group less seroconversion than non-PEP group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What were the percentages for seroconversion for the PEP group vs non PEP group in the PEP Brazil study?

A

1.4% vs 7.5%

PEP vs nonpep

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the EXPLORE study for PEPSE?

A

MSM in USA
behavioural intervention trial
No difference HIV seroconversion between PEP vs nonPEP group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What data is there to support PEP in exposure through PWID?

A

LIMITED data

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the 4 reasons for PEPSE failing?

A

1) DELAYED ART start
2) POOR or non- adherence
3) Further HIGH-RISK SEX after PEP stops
4) Early PRIMARY HIV INFECTION already established

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

For PEPSE, what was the adherence to single tablet regimen vs twice daily?

A

71% TDF/FTC/EVG/r vs
57% RAL based (BD) or
39% PI based (BD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

When was the last recorded occupational HIV transmission?

A

1999

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What 3 factors contribute to the risk of HIV transmission through sexual exposure?

A

1) TYPE of sex
2) HIV viral load of INDEX partner
3) SUSCEPTIBILITY of recipient if partner not virologically suppressed ie concomitant STI/GENITAL ULCER DISEASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

HPTN 052 trial - describe what this trial was?

A

Randomised control trial (RCT)

Heterosexual serodiscordant couples

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HPTN 052 trial - what were the outcomes?

A

8 linked transmissions

  • 4 prior to full viral suppression
  • 4 related to treatment failure/detectable VL
  • None if VL undetectable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PARTNER trial - describe what this trial was?

A
  • Europe
  • Prospective observational
  • Gay and HETEROSEXUAL, discordant couples
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

PARTNER trial - what were the outcomes?

A

888 couples

No linked transmissions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PARTNER 2 - describe this trial?

A
  • Extension of PARTNER to improve understanding of transmission risk for MSM
  • Prospective observational
  • MSM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

PARTNER 2 - what were the outcomes?

A

782 couples

No linked transmissions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

OPPOSITES ATTRACT - describe this trial

A

Small observational

MSM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

OPPOSITES ATTRACT - what were the outcomes?

A

232 couples

No linked transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What FOUR trials support the statement U=U?

A

HPTN 052
PARTNER
PARTNER 2
OPPOSITES ATTRACT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the estimated prevalence of DETECTABLE HIV viraemia in England for MSM?

A

23/1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the estimated prevalence of DETECTABLE HIV viraemia in England for PWID?

A

6.7/1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Is the estimated prevalence of DETECTABLE HIV viraemia for PWID higher for men or women?

A

WOMEN

11 per 1000 vs 5 per 1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

estimated prevalence of DETECTABLE HIV viraemia in heterosexual non-Black African MEN?

A

Very low

0.2 per 1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

estimated prevalence of DETECTABLE HIV viraemia in heterosexual non-Black African WOMEN?

A

Very low

0.1 per 1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Is the estimated prevalence of DETECTABLE HIV viraemia for Black Africans higher for men or women?

A

WOMEN

8.7 per 1000 vs 5.8 per 1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is the risk of HIV transmission with RECEPTIVE anal sex + EJACULATION?

A

1 in 65

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is the risk of HIV transmission with RECEPTIVE anal sex + no ejaculation?

A

1 in 170

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What is the risk of HIV transmission with INSERTIVE anal sex + CIRCUMCISION?

A

1 in 909

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the risk of HIV transmission with INSERTIVE anal sex + no circumcision?

A

1 in 161

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Which specific exposures involving anal sex have very similar risks?

A

Receptive + no ejaculation
(1 in 170)
Insertive + no circumcision
(1 in 161)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What is the risk of HIV transmission with RECEPTIVE vaginal sex?

A

1 in 1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What is the risk of HIV transmission with INSERTIVE vaginal sex?

A

1 in 1219

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Which is highest risk, receptive or insertive VAGINAL sex?

A

Receptive

1 in 1000 vs 1 in 1219

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What TWO exposure types have risk of HIV transmission 1 in 1000?

A

receptive vaginal

mucocutaneous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is the risk of HIV transmission with SEMEN SPLASH into eye?

A

<1 in 10000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What is the risk of HIV transmission with ORAL sex?

A

< 1 in 10 000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What is the risk of HIV transmission with a human BITE?

A

< 1 in 10 000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What is the risk of HIV transmission with blood TRANSFUSION?

A

1 in 1 (ie 100%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What is the risk of HIV transmission with NEEDLESTICK injury?

A

1 in 333

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What is the risk of HIV transmission with sharing injecting equipment inc chemsex?

A

1 in 149

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What THREE exposure types have risk of HIV transmission <1 in 10 000?

A

SEMEN SPLASH to eye
ORAL sex
Human BITE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

How do you calculate risk of HIV transmission?

A

Risk of HIV transmission =

Risk per type of EXPOSURE x risk that source is HIV positive with detectable viral load (ie population)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What FIVE factors in the index case increase the risk of HIV transmission if NOT on ART?

A

1) High VL
2) Breaches of mucosal barrier
3) Menstruation
4) Pregnancy/post partum
5) STI or genital ulcer disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

If the index case has a detectable viral load what impact does this have on the risk of HIV transmission?

A

2.9 fold increase per act with each log10 increase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Through what THREE scenarios might an occupational exposure occur?

A

Contact with bodily fluids or tissue

1) PERCUTANEOUS
2) MUCOUS MEMBRANE (or non-intact skin)
3) BITE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Which Body fluids are implicated in the transmission of HIV?

A

Blood, semen, vaginal secretions
CSF
Synovial, pleural, peritoneal, pericardial or amniotic fluid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Which Body fluids are NOT implicated in the transmission of HIV?

A 
faeces, 
nasal secretions, 
saliva,
gastric secretions, 
sputum, 
sweat, 
tears, 
urine or 
vomit.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

In which situation might there be a risk of HIV transmission in the bodily fluids not typically implicated in infection?

A

If there is blood in them

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What FOUR factors increase the risk of HIV seroconversion in the event of percutaneous injury?

A

1) DEEP injury
2) VISIBLE BLOOD on device
3) Needle in VEIN or ARTERY
4) AIDS in index case

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

What is the risk of HIV transmission through non-intact skin?

A

Negligible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Have there been any reported cases of HIV transmission through non-intact skin?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

What is the risk of HIV transmission through SPITTING and BITING?

A

Spitting - NO risk

Biting - NEGLIGIBLE (increased if blood in saliva and high VL index case)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

What factors have been present when HIV transmission occurred through a bite?

A 
Index case:
HIGH viral load,
BLOOD in mouth
and
DEEP or MULTIPLE bites
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

HIV outbreak in PWID in Glasgow - describe

A 
Identified 2015
Ongoing
HIV prevalence increased
0.1% to 4.8% overall
1.1% to 10.8% Glasgow city centre
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

What are the THREE main drugs used in chemise?

A

1) crystal methamphetamine
2) GHB/GBL
3) ephedrine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

What is the reason for taking ‘chems’?

A

SUSTAIN or ENHANCE the experience of sex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

What is an alternative term for ‘injecting’ drugs in the context of chemsex?

A

‘slamming’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

What proportion of MSM partake in chemsex?

A

17%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

What proportion of MSM partaking in chemsex, inject drugs?

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

There are FOUR categories of PEP recommendation - what are they?

A

RECOMMENDED
CONSIDER
GENERALLY NOT recommended
NOT RECOMMENDED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

What is the definition of ‘PEP RECOMMENDED’?

A

Benefits of PEP outweigh risk

PEP should be given unless clear reason not to

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

What is the definition of ‘CONSIDER PEP’?

A

RISK of HIV transmission LOW
Risk vs benefit balance less clear
requires CASE by CASE assessment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

What is the definition of ‘PEP GENERALLY NOT RECOMMENDED’?

A

risk of HIV transmission VERY LOW
potential TOXICITY of PEP likely outweighs benefit
PEP will very rarely be given

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

What is the definition of ‘PEP NOT RECOMMENDED’?

A

NEGLIGIBLE risk of HIV

PEP should NOT be given

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

What information is important to get from the index case of a potential HIV transmission?

A

HIV status
Viral load
ART - on or off
Past virological failure or resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

If the index case is known to be HIV positive with detectable VL what is the calculation used to establish risk of transmission?

A

1 x risk per exposure

ie Risk of HIV transmission = risk that source is HIV positive with a detectable HIV viral load X risk per exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

What study types support U=U with regards to sexual exposure?

A

RCT

Observational studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

What THREE factors in the PLWHIV need to be met to guarantee U=U?

A

1) UNDETECTABLE VL
2) ART SIX (6) months
3) Good ADHERENCE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Is PEP recommended for oral sex with ejaculation?

A

NO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

What is the risk of HIV transmission for oral sex with ejaculation?

A

<1/10 000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

What factors may increase the risk of HIV transmission for oral sex?

A

Recent dental procedures
Pharyngitis
Chemotherapy
Periodontal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

In what extreme circumstances can PEP be considered for oral sex?

A

1) PRIMARY HIV INFECTION of index

2) oropharyngeal TRAUMA/ULCERATION

76
Q

Is PEP for sexual assault generally recommended in the UK?

77
Q

In what situation might PEP be more readily considered in event of sexual assault?

A

Assailant is from HIGH PREVALENCE group

78
Q

What is the prevalence of HIV in female sex workers in WESTERN EUROPE?

79
Q

What is the prevalence of HIV in female sex workers in CENTRAL EUROPE?

80
Q

What is the prevalence of HIV in female sex workers in EASTERN EUROPE?

81
Q

What lifestyle factor increases prevalence of HIV In female sex workers?

A

INJECTING DRUG USERS

82
Q

What is the prevalence of HIV in MALE sex workers?

83
Q

What is the evidence to support U=U in context of percutaneous injury?

A

There is none

84
Q

When considering PEP for a percutaneous injury and index case with HIV, what information should be given to the patient?

A
  • Highly likely viral suppression (undetectable) eliminates the risk of HIV transmission
  • Lack of evidence to fully support
85
Q

Should PEP be recommended in a community needlestick exposure?

86
Q

What is the summary of risk of HIV transmission from a community needlestick exposure?

A

Extremely low risk

87
Q

Has there ever been a reported case of HIV transmission from a community needlestick exposure?

88
Q

How do you calculate the maximum potential risk of HIV transmission from a community needlestick exposure? And in what setting only should it be used?

A

Risk of HIV transmission
= risk that source is HIV positive with a detectable viral load X
0.3 (risk per exposure)

Only use if recipient is confident freshly discarded needle

89
Q

How quickly does HIV become non-viable in dried blood?

A

TWO (2) hours

90
Q

In what situation ONLY would PEP be considered for a bite injury?

A 
Biter:
1) SALIVA visibly contaminated with BLOOD
2) known DETECTABLE viral load
Injury:
3) SEVERE or DEEP
91
Q

What specific information is important to get from index case who are PWID?

A

CURRENT injecting

SHARING equipment

92
Q

What is the recommended regimen for PEP?

A

Tenofovir disoproxil 245mg/emtricitibine 200mg
+
raltegravir 1200mg

93
Q

What TWO factors may change the PEP regimen?

A

1) Past or current history of ART FAILURE OR RESISTANCE in index case
2) PREGNANCY

94
Q

What is the recommended regimen for PEP in PREGNANCY?

A

Tenofovir disoproxil 245mg/emtricitibine 200mg
+
RALTEGRAVIR 400mg twice daily

95
Q

If 400mg raltegravir is not available for pregnant person how should the PEP regimen be altered?

A

Raltegravir 600mg twice daily

Switch to 400mg as soon as available

96
Q

Why is tenofovir disoproxil based regimens preferred over zidovudine?

A

Higher completion rates

Less adverse events causing discontinuation of PEP

97
Q

When would tenofovir alafenamide (TAF) be used instead of TDF for PEP?

A

Chronic kidney disease

eGFR <50ml/min

98
Q

What is the limitation of using TAF in PEP regimen?

A

No in-human data

99
Q

What evidence supports the theoretical utility of TAF in a PEP regimen?

A

PrEP trials (for MSM)

100
Q

What are the VERY common (>1/10) side effects with TDF/FTC?

A

Headache,
dizziness,
diarrhoea,
nausea

101
Q

What are the COMMON (1/10-1/100) side effects with TDF/FTC?

A

insomnia,

abdominal pain

102
Q

What is the main risk associated with TDF, other than side effects?

A

Renal toxicity

103
Q

What are the concerns about using raltegravir 1200mg once daily for PEP?

A

More hygroscopic
Must be stored in original moisture protected packaging
Cannot divide pack into start packs
Minimum duration available 30 days

104
Q

Why is raltegravir preferred integrase inhibitor for PEP?

A

1) SAFE in pregnancy
2) COST
3) good TOLERABILITY

105
Q

What are the most common side effects when using integrase inhibitors for PEP?

A

diarrhoea
nausea
headache

106
Q

If using dolutegravir for PEP what side effect should be considered and risk assessed for?

A

CNS effect resulting in

SUICIDAL ideation or behaviour

107
Q

In a study in Belfast assessing tolerability of RAL in PEP, what proportion experience side effects?

108
Q

What is the limiting factor for use of elvitegravir/cobicistat in PEP?

A

Drug-drug INTERACTION with cobicistat

109
Q

What is a potentially useful aspect of elvitegravir/cobicistat for use as PEP?

A

Can be used with TDF/FTC as SINGLE TABLET regimen

110
Q

1 seroconversion occurred in a study looking at TDF/FTC/EVG/c as PEP, what was this attributed to?

A

MULTIPLE EXPOSURES before and after PEP initiation

111
Q

What is the limiting factor for use of dolutegravir in PEP?

A

Risk of NEURAL TUBE DEFECT in PREGNANCY

112
Q

Instead of integrase inhibitors what else can be used as 3rd agent for PEP?

A

Protease inhibitors

113
Q

What PROTEASE INHIBITORS can be used in PEP?

A

DARUNAVIR/ritonavir
or
ATAZANAVIR/ritonavir

114
Q

What pharmacokinetic BOOSTER is used with PI for PEP?

115
Q

If using TAF/emtricitibine (Descovy) what DOSE is used with INTEGRASE inhibitors?

A

TAF 25mg/

emtricitibine 200mg

116
Q

If using TAF/emtricitibine (Descovy) what DOSE is used with PROTEASE inhibitors?

A

TAF 10mg/

emtricitibine 200mg

117
Q

SWALLOWING difficulties - TDF/FTC - how to manage?

A

DISSOLVE in
100ml
WATER or ORANGE juice

118
Q

SWALLOWING difficulties - LOPINAVIR/RITONAVIR - how to manage?

A

LIQUID formulation

119
Q

Which ART is available in liquid form and can be used in PEP?

A

LOPINAVIR/ritonavir

120
Q

SWALLOWING difficulties - DOLUTEGRAVIR - how to manage?

A

SPLIT or CRUSH

add to SEMI-SOLID food

121
Q

What is the prevalence of NNRTI resistance in the UK?

122
Q

Why are NNRTI not recommended in PEP?

A

Significant RESISTANCE in UK

123
Q

Why are protease inhibitors not first line for PEP?

A

1) DDI (esp risk of recreational drug use in MSM)

2) SIDE EFFECTS

124
Q

Through what mechanism are PIs implicated in drug-drug interactions?

A

Cytochrome p450 INHIBITOR

INCREASES drug levels metabolised through same pathway

125
Q

What FOUR common classes of medication are INCREASED through CYP450 pathway when protease inhibitors are used?

A

1) CORTICOSTEROIDS
2) RECREATIONAL DRUGS
3) ANTIBIOTICS
4) ANTIPSYCHOTICS

126
Q

Can MARAVIROC be used as PEP?

A

under INVESTIGATION

127
Q

What are the beneficial properties of MARAVIROC that make it potential for use as PEP?

A

TOLERABILITY

Very high levels GENITAL TRACT

128
Q

Why is maraviroc not currently recommended as PEP?

A

1) Potential for non-CCR5-tropic HIV to be transmitted

2) Not currently first line HIV treatment

129
Q

What mode of action is MARAVIROC in HIV?

A

CCR5 chemokine receptor INHIBITOR

130
Q

If a person has previously been unable to complete PEP due to tolerability or toxicity issues what should be offered?

A

ALTERNATIVE, TAILORED regimen + medication to reduce side effects

131
Q

What may increase the risk of myopathy or rhabdomyolysis when using integrase inhibitors as PEP?

A

History of MYOPATHY

Concomitant medications with risk such as STATINS

132
Q

If antiemetics are required for a protease inhibitor-containing PEP regimen, what ANTIEMETIC should be AVOIDED?

A

DOMPERIDONE

significant DDI

133
Q

Which DIVALENT cations bind to raltegravir in the GI tract?

A

Iron
Magnesium
Calcium
Aluminium

134
Q

Which THREE groups of drugs should be avoided when taking raltegravir, or carefully spaced?

A

1) ANTACIDS
2) IRON supplements
3) MULTIVITAMINS

135
Q

Which ANTIBIOTIC is specifically CONTRAINDICATED with BOOSTED drugs ie PIs and elvitegravir?

A

RIFAMPICIN

136
Q

What evidence supports the 72 hour cut off for PEP start?

A
  • Rhesus MONKEY
  • Intrarectal SIV inoculum study
  • ART started DAY 3 after exposure
  • Blocked emergence of viral RNA and proviral DNA in blood, lymph nodes and GI tract
  • 24 weeks after stopping ART - VIRAL REBOUND
137
Q

What is the evidence to support 28 days of PEP?

A
  • Macaques - IV SIV inoculation
  • PEP start within 24 hours
  • ALL protected with 28 days PEP
  • 50% protected with 10 days PEP
  • ZERO protected with 3 days PEP
138
Q

PEP starter packs (5 days) vs 28 day pack - compare?

A

Low level evidence supports
provision of 28 days at first presentation
- better completion rates

139
Q

What proportion of ED initiated PEP is for a high risk exposure?

140
Q

Prior to starting PEP what THIRTEEN points must be discussed with the patient?

A

1) RATIONALE for PEP
2) LACK of DATA on EFFICACY of PEP
3) START ASAP + importance of ADHERENCE
4) SIDE EFFECTS
5) DDI
6) need for EMERGENCY CONTRACEPTION
7) Symptoms of SEROCONVERSION + urgent medical advice
8) FOLLOW UP
9) HIV TEST
10) 28 DAYS of PEP
11) HIV TEST AT 10.5 WEEKS
12) CONDOMS until fu HIV test post PEP
13) SUPPORT inc MENTAL HEALTH and SOCIAL

141
Q

Is anxiety an indication for PEP?

142
Q

If a person seeking PEP is experiencing anxiety what can be offered?

A

1) Risk assessment for PEP (often identifies low risk and reassuring)
2) Psychological support services

143
Q

What baseline BBV tests should be done on the INDEX case in relation to PEP assessment?

A

HIV Ag/Ab 4th gen
HBsAg
HCV Ab
(or viral load if HIV +ve)

144
Q

What BASELINE tests should be done for the RECIPIENT in relation to PEP assessment?

A 
ALL exposures:
eGFR
ALT
HIV Ag/Ab
HbsAb, sAg & cAb
HCV Ab

SEXUAL exposures: (add)
syphilis

WOMEN of CHILDBEARING potential: (add)
uHCG

145
Q

What FOLLOW UP tests are required after start of PEP?

A 
ALL exposures:
3 months
- HIV Ag/Ab
- HBsAb AND sAg
- HCV Ab
6 months
- HBsAg (if no sAb at 3 months)
- HCV Ab
SEXUAL exposures:
2 weeks
- NAAT for chlamydia/gonorrhoea
3 months
- syphilis serology
146
Q

Are kidney and liver function tests required after starting PEP?

A

No

Consider if history of renal or liver disease

147
Q

Why are kidney and liver function tests NOT required after starting PEP?

A

Renal toxicity REVERSIBLE (PrEP trials)

Low risk of transaminitis with integrase inhibitors

148
Q

What is the earliest point at which an HIV test can be performed after PEP completion?

A 
45 days (ie 10.5 weeks from PEP start)
However more convenient to time in with other 12 week bloods
149
Q

When should hepatitis B vaccination be offered in setting of PEP assessment?

A

Unvaccinated or vaccination status unknown

150
Q

When should hepatitis B immunoglobulin be offered in setting of PEP assessment?

A

If index case is KNOWN HBsAg POSITIVE

151
Q

What dosing regimen of hepatitis B vaccination is suggested in setting of PEP assessment?

A

ULTRA RAPID

0, 7, 21 days and 12 months

152
Q

Describe ULTRA RAPID regimen for hepatitis B vaccination?

A

0, 7, 21 days and 12 months

153
Q

When should hepatitis C core antigen or RNA be checked?

A

If there has been a significant hepatitis C risk ie needlestick from known HCV +ve

154
Q

When can hepatitis C core antigen or RNA be checked in context of high risk exposure?

A

as early as 2 weeks

155
Q

What should be assessed in women of childbearing age requesting PEP?

A

Need for EMERGENCY CONTRACEPTION

Chance of current PREGNANCY

156
Q

What further provision should be offered to people being assessed for PEP who are likely to be at higher risk of HIV acquisition in the future?

A

Referral to sexual health services for risk reduction
CONDOMS
PREP
BEHAVIOUR CHANGE COUNSELLING

157
Q

What proportion of PEP recipients had an STI at baseline?

158
Q

What additional proportion of PEP recipients had an STI at 2 weeks post PEP start?

159
Q

At what time should NAAT testing be offered to PEP recipients?

A 
At baseline (to avoid lost to follow up) and if not sexual assault
2 weeks after exposure
160
Q

If the recipient has HBV chronic infection (sAg +ve) and is started on PEP for HIV exposure, is it safe to stop PEP?

A

iPREX study showed possible to use TDF/FTC in patients with chronic HBV and able to stop without cirrhosis or hepatic flares (however NEEDS SPECIALIST input)

161
Q

What is the complication of starting and then stopping TDF/FTC or 3TC in people with chronic HBV infection?

A

Risk of cirrhosis or hepatic flare

162
Q

Is there a risk for HBV resistance if PEP is given to a person with HBV infection?

A

Extremely UNLIKELY, only 4 weeks therapy

163
Q

If a person is on TDF only to treat HCV infection, do they need to have PEP in the event that they are exposed to HIV?

A

Unclear
Evidence for TDF as PrEP in heterosexual men and women
Should consider PEP especially if MSM

164
Q

Pregnant women are at increased risk of HIV transmission, what could the high viraemia of primary HIV Infection lead to?

A

High likelihood of INTRAUTERINE infection

165
Q

What resource is used to understand the outcomes for pregnancy exposed to ARVs?

A

Antiretroviral Pregnancy Registry

www.apregistry.com

166
Q

What is the antiretroviral pregnancy registry?

A
  • Surveillance study
  • pregnancy outcomes in women exposed to antiretrovirals during pregnancy
  • North America & Europe
167
Q

Which ARVs used in PEP is there good pregnancy safety data?

A 
Tenofovir 
Emtricitibine
Darunavir
Raltegravir
Elvitegravir
168
Q

What is rate of NEURAL TUBE DEFECT in pregnant women on DTG in Botswana vs women on other ARVs?

A

0.19% vs 0.11%

no statistical significance

169
Q

Are ARVs used for PEP licensed for use in pregnant women?

A

No

Need to counsel woman

170
Q

Is breastfeeding a contraindication to PEP?

A

NO

But need to consider individual risk of ART entering breast milk

171
Q

When might PEP be considered in PrEP users?

A

Suboptimal adherence to PrEP

172
Q

When is PEP indicated in PrEP users who have ANAL sex?

A

If less than FOUR (4) pills in past 7 days

173
Q

When is PEP indicated in PrEP users who have VAGINAL, NEO-VAGINAL OR FRONTAL sex?

A

If less than SIX (6) pills in past 7 days

174
Q

What is the HALF-LIFE of RALTEGRAVIR 1200mg daily?

A

8-12 hours

175
Q

What is the HALF-LIFE of TDF/FTC 1200mg daily?

A

12-18 hours
but recent study suggest
31-37 hours

176
Q

What are the missed dose rules for PEP?

A

If less than 48 hours since last dose:
- take dose as soon as remembered
or
- if time for next dose just take that

177
Q

If a PEP dose is missed, how long before PEP should be discontinued?

A

If missed dose for more than 48 hours PEP should be discontinued
(DTG containing is >72 hours)

178
Q

What seroconversion symptoms might present whilst on PEP?

A

Skin rash

Flu-like illness

179
Q

If seroconversion symptoms present whilst on PEP what should the person do?

A

Attend for urgent medical review

180
Q

If an HIV test is positive after PEP has started what should you do?

A

Continue PEP

Refer to HIV specialist

181
Q

Why should ART not be stopped if HIV diagnosis made whilst on PEP?

A

Risk of significant VIRAL REBOUND and therefore INCREASED risk of onward TRANSMISSION

182
Q

What advice should be given if high risk exposure takes place during the last few days of PEP?

A 
ANAL sex and exposure last TWO (2) days of PEP, extend 2 days
VAGINAL sex (or other), ensure PEP continued for 7 days
183
Q

MSM prescribed PEP are associated with higher future HIV acquisition, what is the increase in those who access PEP once?

184
Q

MSM prescribed PEP are associated with higher future HIV acquisition, what is the increase in those who access PEP MORE than once?

185
Q

Repeat PEP users should be offered what?

A

Counselling around safer sex strategies
1 to 1 structured sessions
Condoms
PrEP

DipHIV (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions